Drug Trial Radar · NCT02876328
Partnership for Research on Ebola VACcinations
Last checked: Nov 19, 2026Latest source record: Jun 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,789
Actual
Start
Mar 27, 2017
Primary completion
Dec 24, 2019
Study completion Dec 20, 2023
Sponsor
- Sponsor type
- NIH
- Collaborators
- Partnership for Research on Ebola Virus in Liberia (PREVAIL); Institut National de la Santé Et de la Recherche Médicale, France; London School of Hygiene and Tropical Medicine; European and Developing Countries Clinical Trials Partnership (EDCTP)
- First posted
- Aug 23, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults. Participants will receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA) boost, or the rVSVΔG-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo.
Conditions
- Ebola Virus Disease
Interventions
Ad26.ZEBOVBiological
0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
MVA-BN-FiloBiological
0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
rVSVΔG-ZEBOV-GPBiological
1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
PlaceboBiological
0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
rVSV boostBiological
1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody ResponseTime frame: Measured through Month 12
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
Centre national de formation et de recherche en santé rurale (Maferyniah)
Conakry, Guinea
Landreah
Conakry, Guinea
The Redemption Hospital
Monrovia, Liberia
Centre pour le Développement des Vaccins (CVD)
Bamako, Mali
University Clinical Research Center (UCRC)
Bamako, Mali
Mambolo Clinic
Kapesseh, Sierra Leone
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.